Moderna's shares surged 9% after its Phase 3 melanoma study was selected for a prestigious Presidential Symposium slot at the European Society for Medical Oncology congress. This high-profile placement signals strong confidence in the study's potential impact on clinical practice, even though the actual data will be presented on October 24. Merck, a partner in the study, and BioNTech saw smaller gains, indicating the market's focus is mainly on Moderna. Investors await the detailed data presentation and webcast for further insights and potential stock movement.
Moderna's stock price rose sharply by 9.53% to USD 168.72 on Pluang, reflecting strong market interest ahead of its melanoma study presentation. Merck and BioNTech also gained, with Merck up 1.61% at USD 149.12 and BioNTech up 1.31% at USD 97.32. These prices are as of Sep 21, 2026 23:02 WIB.
Moderna reported a surprise Q3 2026 profit of $0.38 per share versus an expected loss, with revenue rising to $1.31 billion due to strong international COVID-19 vaccine demand. The company raised its 2026 revenue growth forecast to 15-25% and expects...
Moderna's stock price has surged 700% this year amid excitement over its experimental cancer vaccine. However, the company's recent earnings reveal that its revenue growth remains largely driven by strong international demand for its Covid vaccines. ...
Moderna increased its revenue outlook for 2026, now expecting growth between 15% and 25%, up from a previous forecast of 10%. The company, known for its mRNA COVID-19 vaccine Spikevax, cited strong sales as the reason for the optimistic update. This ...
Moderna exceeded third-quarter revenue and earnings expectations, reporting $1.31 billion in revenue and 38 cents earnings per share, compared to analyst estimates of $885.1 million and a loss of $1.25 per share. The company raised its 2026 revenue g...
On November 6, Moderna, Humana, and Elanco will release earnings reports that could impact their stock rallies. Humana's Medicare Advantage update is crucial for retirees, with a focus on medical costs and membership trends. Elanco faces supply chall...
